Szisztémás szklerózis (szkleroderma): vizsgálatok itt: Portugália
5 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleRollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
- Where
- Braga, Lisbon, Porto
- Életkor
- 5 év to 80 év
- People
- 1072 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07691970 - 3. fázisNot yet taking people in PortugáliaRollover Study for Participants Who Have Completed a Previous Clinical Study with Anifrolumab (Saphnelo) and Clinically Benefited from Continued Treatment.
- Where
- Braga, Lisbon
- People
- 340 worldwide
- Run by
- AstraZeneca AB
See details and how to join2026-526419-13-00 - 3. fázisTaking peopleA Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
- Where
- Almada, Coimbra, Lisbon, Ponte De Lima, Porto, Vila Nova de Gaia
- Életkor
- 18 év and over
- People
- 448 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07497087 · EU 2025-523884-39-00 - 2. fázisTaking peoplePlatform Clinical Study for Conquering Scleroderma
- Where
- Amadora, Braga, Coimbra, Lisbon, Ponte De Lima
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Scleroderma Research Foundation, Inc.
See details and how to joinNCT06195072 · EU 2023-507129-40-00 - 2. fázisTaking peopleAlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Where
- Lisbon, Vila Nova de Gaia
- Életkor
- 18 év and over
- People
- 90 worldwide
- Run by
- Artiva Biotherapeutics, Inc.
See details and how to joinNCT06991114 · EU 2025-520461-41-00